

MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/27/2013; Page 1

Suggested Formula	Rabeprazole Sodium 20 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 001 472v2
----------------------	--	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Rabeprazole Sodium (10 mg) Tablets	40	Units				
Propylene Glycol, USP	20.0	mL				
Sodium Bicarbonate, USP	8.40	g				
Medisca Oral Suspend (Suspending Vehicle)	30.0	mL				
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 100.0	mL				
Sodium Hydroxide 10% Solution	As required					

SPECIAL PREPARATORY CONSIDERATIONS

<u>Ingredient-Specific Information</u>		
Light Sensitive (protect from li	ght whenever possible):	Propylene Glycol
Moisture Sensitive (protect fro	m humidity whenever possible):	Rabeprazole Sodium, Sodium Bicarbonate
Hygroscopic (protect from moi	sture whenever possible):	Propylene Glycol
Suggested Preparatory Guidelines		
Non-Sterile Preparat	ion	
Processing Error / Testing Considerations:		and pH testing considerations during preparation, it is al 5 to 9% of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab c should always be worn.	coat, disposable gloves, eyewear and face-masks
		f very small quantities of ingredients. All calculations be verified before dispensing the final product.



TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/27/2013; Page 2

Suggested Formula	Rabeprazole Sodium 20 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 001 472v2
----------------------	--	-----	-------------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Rabeprazole Sodium (10 mg) Tablets §	40	Units			
Propylene Glycol, USP §	20.0	mL			
Sodium Bicarbonate, USP §	8.40	g	(a)		
Medisca Oral Suspend (Suspending Vehicle)	30.0	mL			
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 100.0	mL) Y C.		
Sodium Hydroxide 10% Solution	As required				

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.



TOLL-FREE: 866-333-7811
TELEPHONE: 514-905-5096
FAX: 514-905-5097
technicalservices@medisca.net

4/27/2013; Page 3

	Preparatory Instruction		
	redient quantification (determine the actual quantity of Rabeprazole Sodium (10 mg) igh if accounting for processing error adjustments):	tablet pow	der to
	Weigh the 44 x Rabeprazole Sodium (10 mg) Tablets. Record the total weight here:		ď
			g
В.	Calculate the average weight of powder in each tablet:		
	Weight of 44 tablets (from Step 1A):		g
	DIVIDED BY		
	Number of tablets	4	4
	EQUALS		
	Average weight of a single Rabeprazole Sodium (10 mg) Tablet:		g
ļ			
C.	Calculate the weight of powder equivalent to 40 tablets:		
	Average weight of a single Rabeprazole Sodium (10 mg) Tablet (from Step 1B):		g
	MULTIPLED BY		
	Number of tablets required:	4	0
	EQUALS		
	Weight of powder equivalent to 40 tablets:		g
D.	Calculate the weight of powder required <i>plus</i> processing error adjustments:		
	Weight of powder equivalent to 40 tablets (from Step 1C):		g
	MULTIPLED BY		
	Processing error adjustments (5 to 9%):	1.05 to	1.09
	EQUALS		
	Weight of powder required <i>plus</i> processing error adjustments:		g



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/27/2013; Page 4

Suggested Formula	Rabeprazole Sodium 20 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 001 472v2
----------------------	--	-----	-------------

2. **Powder preparation:**

- A. Crush and triturate the 44 Rabeprazole Sodium (10 mg) Tablets to form a fine, homogeneous powder.
- B. Weigh the quantity of Rabeprazole Sodium (10 mg) tablets powder required for the batch (refer to Step 1D) and discard the remaining powder.

3. **Liquid preparation:**

- A. Combine and triturate the following ingredients together to form a fine, homogeneous powder blend:
 - -Fine, homogeneous powder (amount weighed in Step 2B)
 - -Sodium Bicarbonate
- B. Levigate the fine, homogeneous powder blend (Step 3A) with the Propylene Glycol.

End result: Homogeneous paste-like dispersion.

4. **Medium integration:**

A. Incrementally add the homogeneous paste-like dispersion (Step 3B) to the Oral Suspend (Suspending Vehicle).

Specifications: Continuously mix, using high-shear mixing techniques.

End result: Homogeneous liquid-like dispersion.

5. Filling to volume:

A. Add Oral Syrup (Flavored Vehicle) to the mixture (Step 4A) to fill to the required batch size (100.0 mL *plus* processing error adjustments).

Specifications: Continuously mix, using high-shear mixing techniques.

End result: Homogeneous liquid-like dispersion.

6. **pH testing:**

- A. Draw an appropriate amount of the mixture (Step 5A).
- B. Test the pH of the sample. It should lie between 8.3 and 8.7
- C. If the pH < 8.3, carefully add in a dropwise manner the Sodium Hydroxide 10% solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% solution.
 - 3. Re-test the pH.
 - 4. Continue to add the Sodium Hydroxide 10% solution until the pH of 8.3 to 8.7 is obtained.

IMPORTANT: Do not allow the pH to rise above 8.7



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/27/2013; Page 5

Suggested Formula	Rabeprazole Sodium 20 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 001 472v2
----------------------	--	-----	-------------

7. **Product transfer:**

A. Transfer the final product into the specified dispensing container (see "Packaging requirements").

<u>Note</u>: Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.

SUGGESTED PRESENTATION

IGGESTED PRI		NIATION			
Estimated Beyond-Use Date		14 days, refrigerated, as per USP.	as per Packaş Requireme		 Tightly closed, light-resistant dispensing bottle. To be administered with a metered dose-measuring device.
Aurilian	Use as directed. Do not exceed dose.		ed prescribed		Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
Auxiliary Labels 2 Keep out of reach of children.		6	Cap tightly after use.		
	3	3 Keep refrigerated. Do not freeze.		7	Shake well before use.
	4	Protect from light.			
Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. CAUTION: SAFETY AND EFFICACY OF RABEPRAZOLE IS NOT ESTABLISHED IN CHILDREN UNDER 18 YEARS.					F RABEPRAZOLE IS NOT
Patient Instructions	Contact your pharmacist in the event of adverse reactions				



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/27/2013; Page 6

Suggested Formula	Rabeprazole Sodium 20 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 001 472v2	
----------------------	--	-----	-------------	--

REFERENCES

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 167.
2.	Pariet. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2005. 1533.
3.	Propylene Glycol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 4 th Edition. American Pharmaceutical Association; 2003: 521.
4.	Sodium Bicarbonate. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 4 th <i>Edition</i> . American Pharmaceutical Association; 2003: 552.
5.	Rabeprazole Sodium. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 34 th Edition. London, England: The Pharmaceutical Press; 2005: 1285.
6.	Rabeprazole Sodium (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 1450.
7.	USP <795>. US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20</i> . Rockville, MD: US Pharmacopeial Convention, Inc; 2001: 2053.
8.	Rabeprazole Sodium. US Pharmacopeial Convention, Inc. <i>USP DI – Drug Information for the Health Care Professional</i> , 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2564.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.